Helsinn Establishes New R&D Hub in the U.S. to Support its Global Fully Integrated Targeted Therapy (FITT) Strategy 30 Maggio 2022
Helsinn to present data at upcoming AMMF’s 2022 European Cholangiocarcinoma Conference 17 Maggio 2022
Knight Therapeutics and Helsinn Healthcare SA Enter into Exclusive License, Distribution, and Supply Agreement for Akynzeo® and Aloxi® 17 Maggio 2022
United States Ambassador Scott Miller meets the Chairman of Farma Industria Ticino Association 12 Maggio 2022
Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets* 9 Maggio 2022
Zambon Receives U.S. FDA Breakthrough Therapy Designation for CMS I-neb® in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFB) 27 Aprile 2022
FIT premia il miglior lavoro di diploma nella Tecnica dei sistemi chimico-farmaceutica della SSST 29 Marzo 2022
Taiho Pharmaceutical Obtains Approval to Manufacture and Market NK1 Receptor Antagonist Arokaris® I.V. Infusion 235mg in Japan 28 Marzo 2022
Febbraio 2022: il settore chimico–farmaceutico spinge le esportazioni a un nuovo un livello record 17 Marzo 2022
Linkedin